System for the biocontrol of disease-transmitting mosquitoes and their eggs using horizontally transferable symbiotic bacteria to deliver pathogen specific interfering RNA polynucleotides
The inventive technology relates to novel paratransgenic strategies for the control of pathogens. The inventive technology may specifically include a novel paratransgenic system configured to deliver one or more inhibitory RNA molecules to pathogen/disease-transmitting organisms. In a preferred embodiment, the invention may include one or more genetically engineered symbiotic bacteria configured to persist throughout the life-cycle of a mosquito and deliver one or more interfering RNA molecules to pathogen/disease-transmitting mosquitoes.
1. A method comprising:
introducing into a mosquito a genetically modified bacteria that colonizes the mosquito, wherein the bacteria includes a nucleotide sequence, operably linked to a promoter, encoding a heterologous double stranded RNA (dsRNA) polynucleotide that inhibits expression of an essential gene of a Zika virus, or a Dengue virus present in the mosquito, wherein said dsRNA polynucleotide is selected from the nucleotide sequence of SEQ ID NO.'s 1, 2, 3, 4, 5 and 8;
wherein expression of the dsRNA polynucleotide within the mosquito inhibits expression of the Zika virus, or the Dengue virus.
2. The method of claim 1 , wherein the mosquito is selected from the group consisting of: a female mosquito, a mosquito larvae, a third instar larva, a pupa, a mosquito egg, and an adult mosquito.
3. The method of claim 1 , wherein said genetically modified bacteria is obtained from: Enterobacter spp., Rhizobium radiobacter , and Pseudomonas putida.
4. The method of claim 1 , wherein said genetically modified bacteria further comprises a genetically modified symbiotic bacteria being further modified to express a nucleotide sequence, operably linked to a promoter, encoding a heterologous VrrA small-non-coding RNA (sRNA) comprising the nucleotide sequence of SEQ ID NO. 7.
5. The method of claim 1 , wherein the essential gene is from said Zika virus, and said essential gene is selected from the group consisting of: NS2B, NS3, and NS4.
6. The method of claim 1 , wherein said genetically modified bacteria is obtained from: E. coli strain JC8031, an autotropic endosymbiotic enteric bacteria, an RNase III deficient endosymbiotic enteric bacteria, E. coli strain HT115, E. coli strain HT27, E. coli strain JC8031, Pantoea strain Ae16, Serratia strain AeS1, Serratia strain MS5, Pseudomonas putida strain Ae076, or Pseudomonas putida Ae171.
7. The method of claim 1 , wherein the bacteria further expresses a second nucleotide sequence, operably linked to a promoter, encoding the heterologous dsRNA selected from the group consisting of: the nucleotide sequence of SEQ ID NO.'s 9, 10, and 11.
8. A method comprising the steps of:
generating a genetically modified bacteria, that colonizes a mosquito, wherein the bacteria includes a nucleotide sequence, operably linked to a promoter, encoding a heterologous RNA polynucleotide that downregulates expression of at least one Zika virus gene, or at least one Dengue virus gene, and wherein said genetically modified bacteria is RNase III deficient; and
introducing into the mosquito an effective amount of said genetically modified bacteria that colonizes the mosquito and expresses the heterologous RNA polynucleotide that downregulates expression of the at least one Zika virus gene, or the at least one Dengue virus gene; and
wherein the nucleotide sequence encoding the heterologous RNA polynucleotide is selected from the group consisting of the nucleotide sequence of SEQ ID NO.'s 1, 2, 3, 4, 5 and 8.
9. The method of claim 8 , wherein said mosquito is of a species selected from the group consisting of: Aedes aegypti, Aedes albopictus , and Anopheles gambiae.
10. The method of claim 9 , wherein said mosquito is selected from the group consisting of: a female mosquito, a mosquito larvae, a third instar larva, a pupa, a mosquito egg, and an adult mosquito.
11. The method system of claim 8 , wherein said inhibitory RNA polynucleotide is a dsRNA polynucleotide molecule.
12. The method of claim 11 , wherein the bacteria further expresses a heterologous VrrA sRNA comprising the nucleotide sequence of SEQ ID NO. 7.
13. The method of claim 11 , wherein said Zika virus gene is selected from the group consisting of: NS2B, NS3, and NS4.
14. The method of claim 8 , wherein the bacteria further expresses a second nucleotide sequence, operably linked to a promoter, encoding the heterologous dsRNA selected from the group consisting of: the nucleotide sequence of SEQ ID NO.'s 9, 10, and 11.